Regulus Therapeutics Inc (RGLS)
$2.21
Insights on Regulus Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 10.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 315.2%
Performance
- $2.19$2.32$2.21
0.9%
Downside
Day's Volatility :5.6%
Upside
4.74%
- $1.08$3.79$2.21
51.13%
Downside
52 Weeks Volatility :71.5%
Upside
41.69%
Returns
| Period | Regulus Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 48.32% | 0.0% |
6 Months | 57.86% | 0.0% |
1 Year | 61.31% | 0.0% |
3 Years | -80.09% | -22.6% |
Highlights
Market Capitalization | 149.9M |
Book Value | $1.05 |
Earnings Per Share (EPS) | -1.44 |
PEG Ratio | -0.04 |
Wall Street Target Price | 7.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -50.2% |
Return On Equity TTM | -110.27% |
Revenue TTM | 5.0M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 27677.800000000003% |
Gross Profit TTM | -18.4M |
EBITDA | -30.9M |
Diluted Eps TTM | -1.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.62 |
EPS Estimate Next Year | -0.75 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.11 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 234.84%
Technicals Summary
Sell
Neutral
Buy
Regulus Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Regulus Therapeutics Inc | -9.05% | 57.86% | 61.31% | -80.09% | -81.11% |
 Moderna, Inc. | 19.0% | 85.08% | 12.75% | -28.27% | 721.13% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
 Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Regulus Therapeutics Inc | NA | NA | -0.04 | -0.62 | -1.1 | -0.5 | NA | 1.05 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Regulus Therapeutics Inc | Buy | $149.9M | -81.11% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 721.13% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
Institutional Holdings
Federated Hermes Inc
19.63%RA Capital Management, LLC
9.55%Vivo Capital, LLC
7.64%Adage Capital Partners Gp LLC
5.62%Deep Track Capital, LP
4.99%FMR Inc
4.46%
Company Information
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Organization | Regulus Therapeutics Inc |
Employees | 30 |
CEO | Mr. Joseph P. Hagan M.B.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.21
+0.0%
Keyarch Acquisition Corp
$2.21
+0.0%
Connexa Sports Technologies Inc
$2.21
+0.0%
Us Value Etf
$2.21
+0.0%
First Wave Biopharma Inc
$2.21
+0.0%
Global X Msci Next Emerging
$2.21
+0.0%
Fat Projects Acquisition Corp
$2.21
+0.0%
Goal Acquisitions Corp
$2.21
+0.0%
Capital Link Global Fintech
$2.21
+0.0%